Combating Myopia – from epidemiology to clinical interventions
Other conference paper



摘要Myopia is a global health threat. By year 2025, it is predicted approximately 50% and 10% of world’s population being
myopic and highly myopic, respectively. Notably, high myopia is associated with sight-threatening complications, including presenile cataract, glaucoma, retinal detachment, and choroidal neovascularization etc. A comprehensive approach to study its prevalence, risk factors, and clinical interventions is important for effective myopia control. In this lecture, the author will present his works on myopia, including Hong Kong Children Eye Study (HKCES) and Low- concentration Atropine for Myopia Progression (LAMP) Study.

The HKCES is an ongoing population-based cohort of children aged 6-8 years and their parents. Our first phase has
determined the prevalence and risk factors of childhood myopia, together with its parental influences. Entering into our
second phase, the cohort is recruiting a total of 30,000 families for detailed phenotype and genotype evaluations, and biobank establishment.

The LAMP Study is the first placebo-controlled randomized controlled trial of 438 children aged 4 to 12 years on low-concentration atropine of 0.05%, 0.025%, 0.01%, and placebo. Our first phase has proven that low-concentration atropine is effective compared with placebo control, and that 0.05%, 0.025%, and 0.01% atropine reduce myopia progression along a concentration-dependent response, and were all well tolerated. Compared with placebo group at 1 year, 0.05%, 0.025% and 0.01% atropine eye drops confer a respective reduction of 67%, 43%, 27% in spherical equivalent progression, and 51% 29%, 12% in axial length elongation.
著者Yam JCS
會議名稱Nakajima Award Lecture, APAO Congress 2019

上次更新時間 2020-08-04 於 21:56